This company is no longer active
Resumen de acción 0P0
Aerie Pharmaceuticals, Inc., a pharmaceutical company, focuses on the discovery, development, and commercialization of ophthalmic therapies for open-angle glaucoma, dry eye, diabetic macular edema, and wet age-related macular degeneration in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Recompensas
Análisis de riesgos
Competidores de Aerie Pharmaceuticals, Inc.
Historial de precios y rendimiento
| Historical stock prices | |
|---|---|
| Current Share Price | US$14.50 |
| 52 Week High | US$15.70 |
| 52 Week Low | US$4.58 |
| Beta | -0.062 |
| 1 Month Change | -5.23% |
| 3 Month Change | 33.03% |
| 1 Year Change | 63.84% |
| 3 Year Change | -14.71% |
| 5 Year Change | -71.88% |
| Change since IPO | 16.98% |
Noticias y actualizaciones recientes
Recent updates
Rentabilidad de los accionistas
| 0P0 | DE Pharmaceuticals | Mercado DE | |
|---|---|---|---|
| 7D | 0% | -4.2% | -1.7% |
| 1Y | 63.8% | -32.1% | -0.2% |
Rentabilidad vs. Industria: 0P0 exceeded the German Pharmaceuticals industry which returned -10.8% over the past year.
Rentabilidad vs. Mercado: 0P0 exceeded the German Market which returned -21.6% over the past year.
Volatilidad de los precios
| 0P0 volatility | |
|---|---|
| 0P0 Average Weekly Movement | 10.9% |
| Pharmaceuticals Industry Average Movement | 6.9% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.0% |
| 10% least volatile stocks in DE Market | 2.4% |
Precio estable de las acciones: 0P0's share price has been volatile over the past 3 months.
Volatilidad a lo largo del tiempo: 0P0's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of German stocks.
Acerca de la empresa
| Fundada | Empleados | CEO | Página web |
|---|---|---|---|
| 2005 | 376 | Raj Kannan | www.aeriepharma.com |
Resumen de fundamentos de Aerie Pharmaceuticals, Inc.
| Estadísticas fundamentales de 0P0 | |
|---|---|
| Capitalización bursátil | €735.53m |
| Beneficios(TTM) | -€35.68m |
| Ingresos (TTM) | €208.81m |
3.5x
Ratio precio-ventas (PS)-20.6x
Ratio precio-beneficio (PE)¿Está 0P0 sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
| Cuenta de resultados (TTM) de 0P0 | |
|---|---|
| Ingresos | US$213.94m |
| Coste de los ingresos | US$23.52m |
| Beneficio bruto | US$190.42m |
| Otros gastos | US$226.98m |
| Beneficios | -US$36.55m |
Últimos beneficios comunicados
Sep 30, 2022
Próxima fecha de beneficios
n/a
| Beneficios por acción (BPA) | -0.74 |
| Margen bruto | 89.01% |
| Margen de beneficio neto | -17.09% |
| Ratio deuda/patrimonio | -190.6% |
¿Cómo se ha desempeñado 0P0 a largo plazo?
Ver rendimiento histórico y comparativa